436 related articles for article (PubMed ID: 31272498)
1. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
2. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
3. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
[TBL] [Abstract][Full Text] [Related]
4. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
Manica SR; Sepriano A; Pimentel-Santos F; Gouveia N; Barcelos A; Branco JC; Bernardes M; Ferreira RM; Vieira-Sousa E; Barreira S; Vinagre F; Roque R; Santos H; Madeira N; Rovisco J; Daniel A; Ramiro S
Arthritis Res Ther; 2020 Aug; 22(1):195. PubMed ID: 32825839
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
7. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
8. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis.
Lubrano E; Perrotta FM; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2018 Feb; 45(2):195-201. PubMed ID: 29419448
[TBL] [Abstract][Full Text] [Related]
9. Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.
Ciurea A; Exer P; Weber U; Tamborrini G; Steininger B; Kissling RO; Bernhard J; Scherer A;
Arthritis Res Ther; 2016 Mar; 18():71. PubMed ID: 27000865
[TBL] [Abstract][Full Text] [Related]
10. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
11. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific disparities in disease activity scores among patients with axial spondyloarthritis and their implications for evaluating the response to tumor necrosis factor alpha inhibitor therapy.
Lee S; Kang S; Kim H; Lee J; Kim MJ; Cha HS
Arthritis Res Ther; 2024 Apr; 26(1):90. PubMed ID: 38664785
[TBL] [Abstract][Full Text] [Related]
13. Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort.
Hebeisen M; Neuenschwander R; Scherer A; Exer P; Weber U; Tamborrini G; Micheroli R; Wildi LM; Zufferey P; Nissen MJ; Villiger PM; Bernhard J; Finckh A; van der Horst-Bruinsma IE; Sieper J; Landewé R; van der Heijde D; Ciurea A;
J Rheumatol; 2018 Apr; 45(4):506-512. PubMed ID: 29449504
[TBL] [Abstract][Full Text] [Related]
14. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
[TBL] [Abstract][Full Text] [Related]
15. Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis: going beyond BASDAI.
Marona J; Sepriano A; Rodrigues-Manica S; Pimentel-Santos F; Mourão AF; Gouveia N; Branco JC; Santos H; Vieira-Sousa E; Vinagre F; Tavares-Costa J; Rovisco J; Bernardes M; Madeira N; Cruz-Machado R; Roque R; Silva JL; Marques ML; Ferreira RM; Ramiro S
RMD Open; 2020 Jan; 6(1):. PubMed ID: 32144137
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
[TBL] [Abstract][Full Text] [Related]
18. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
[TBL] [Abstract][Full Text] [Related]
19. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
[TBL] [Abstract][Full Text] [Related]
20. Structural Lesion Progression of the Sacroiliac Joint and Clinical Features in axSpA During TNFi Reduction: A Retrospective Cohort Study.
Mo Q; Dong Y; Ye C; Zhong J; Cai S; Wang M; Dong L
Front Med (Lausanne); 2021; 8():781088. PubMed ID: 34950685
[No Abstract] [Full Text] [Related]
[Next] [New Search]